TriangleCabozantinib + Enfortumab Vedotin (NCT04878029)
Cabozantinib + Enfortumab Vedotin trial for Locally Advanced or Metastatic Urothelial Cancer (NCT04878029). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with urothelial cancer, such as bladder cancer, that is locally advanced or has spread.
The idea: combine cabozantinib, a pill that may stop tumor growth by blocking enzymes cells need, with enfortumab vedotin, given by vein. Enfortumab vedotin is an antibody linked to a toxic agent. The antibody attaches to nectin-4 on cancer cells and delivers the toxin.
The study looks for the best dose, possible benefits, and side effects.
This phase 1 study plans 32 patients. At Emory University's Winship Cancer Institute in Atlanta, Mehmet Bilen leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.